SCHEMBL5197153

SCHEMBL5197153

COc1ccc(-c2ccc(=O)n(Cc3ccc(CO)cc3)c2)cc1

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SDHB P21912 1/20 0.49
▸ CMA1 P23946 1/20 0.46
▸ GRM2 Q14416 1/20 0.46
▸ PDE5A O76074 1/20 0.44
▸ GSK3A P49840 1/20 0.44
▸ GSK3B P49841 1/20 0.44
▸ IDH1 O75874 1/20 0.43
▸ MAPT P10636 4/20 0.43
▸ TP53 P04637 2/20 0.43
▸ CHKA P35790 1/20 0.43
▸ LMNA P02545 1/20 0.43
▸ CHRM1 P11229 2/20 0.43
▸ HRH3 Q9Y5N1 1/20 0.43
▸ CNR1 P21554 1/20 0.42
▸ CNR2 P34972 1/20 0.42
▸ HSP90AA1 P07900 1/20 0.42
▸ MEN1 O00255 1/20 0.42
▸ NPC1 O15118 1/20 0.42
▸ RAB9A P51151 1/20 0.42
▸ KMT2A Q03164 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5445065 0.93 SDHB (0.54) SDHBCMA1GRM2PDE5AGSK3A
SCHEMBL2458827 0.88 CMA1 (0.51) SDHBCMA1GSK3AGSK3BMAPT
SCHEMBL5435867 0.87 SDHB (0.50) SDHBCMA1GRM2PDE5AGSK3A
SCHEMBL5448579 0.87 MEN1 (0.56) SDHBCMA1GRM2PDE5AGSK3A
SCHEMBL5196104 0.86 SDHB (0.49) SDHBCMA1GRM2PDE5AGSK3A
SCHEMBL5430703 0.86 CNR1 (0.52) SDHBCMA1GRM2MAPTCNR1
SCHEMBL5445050 0.86 HRH3 (0.55) SDHBMAPTTP53LMNACHRM1
SCHEMBL5436912 0.85 SDHB (0.47) SDHBCMA1GRM2MAPTCHRM1
SCHEMBL27710864 0.85 CA1 (0.51) SDHBCHRM1MEN1NPC1RAB9A
SCHEMBL5441396 0.85 GRM2 (0.49) SDHBCMA1GRM2PDE5AGSK3A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1799646-B1 NOVEL PYRIDINONE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2-RECEPTORS JANSSEN PHARMACEUTICALS INC (US) 2014-12-10 — — EP disclosed
US-20130109652-A1 NOVEL PYRIDINONE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2-RECEPTORS ADDEX PHARMACEUTICALS S.A. (CH) 2013-05-02 — — US disclosed
US-8399493-B2 Pyridinone derivatives and their use as positive allosteric modulators of mGluR2-receptors Janssen Pharmaceuticals, Inc. (US) 2013-03-19 — — US disclosed
US-20070213323-A1 NOVEL PYRIDINONE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2-RECEPTORS Janssen Pharmaceuticals, Inc. 2007-09-13 — — US disclosed
EP-1799646-A1 NOVEL PYRIDINONE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2-RECEPTORS JANSSEN PHARMACEUTICA N.V. (BE) 2007-06-27 — — EP disclosed
WO-2006030032-A1 NOVEL PYRIDINONE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2-RECEPTORS JANSSEN PHARMACEUTICA N.V. (BE) 2006-03-23 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070213323-A1 NOVEL PYRIDINONE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2-RECEPTORS GRM2, GRM1, GRM3 SDHB 1074/4885CMA1 4671/4885GRM2 1/4885
US-20130109652-A1 NOVEL PYRIDINONE DERIVATIVES AND THEIR USE AS POSITIVE ALLOSTERIC MODULATORS OF MGLUR2-RECEPTORS GRM2, GRM1, GRIA2 SDHB 1134/4885CMA1 4632/4885GRM2 1/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback